BRCA1 and ovarian carcinoma: Rucaparib was approved for advanced BRCA1/2 mutated ovarian carcinomas following multiple chemotherapy treatments, while niraparib was approved for homologous recombination deficiency (HRD)-positive gynecological cancers (Franzese et al., 2019; Kim and Nam, 2022).